Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation.
Next review: Recommendation 1.1 will be considered for review in 2023.
Recommendation 1.2 will be updated after June 2020 when more evidence on olaparib has been collected. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
There is a simple discount patient access scheme and a commercial access agreement for olaparib. These form part of the managed access agreement when olaparib is used in the Cancer Drugs Fund. Contact Market.AccessUK@astrazeneca.com for details.
This guidance updates and replaces NICE technology appraisal guidance 381